J. A. Jakubowski (1), N. Bourguet (2), D. Boulay-Moine (2), A. Sugidachi (3), S. Yamaguchi (4), P. Barragan (5), C. Zhou (1), M. Moulard (2)
(1) Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA; (2) Biomarkers, BioCytex, Marseille, France; (3) Biological Research Laboratories, Daiichi Sankyo Company, Ltd., Tokyo, Japan; (4) Cardiovascular-Metabolics Research Laboratories, Daiichi Sankyo Company, Ltd., Tokyo, Japan; (5) Département de Cardiologie Interventionnelle, Polyclinique des Fleurs, Ollioules, France
Thienopyridines and other agents target the platelet P2Y12 receptor and inhibit several platelet activities mediated by adenosine diphosphate (ADP). The measurement of vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation, expressed as platelet reactivity index (PRI), mirrors the degree of P2Y12 receptor inhibition and can detect the well-known variable response to clopidogrel. The commercially available VASP assay uses flow cytometry (FC) and requires that the test be run within 48 hours of blood collection. A new ELISA VASP assay offers the advantages of using more widely available technology and the potential to freeze and store samples before analysis. The objectives of the present study were to compare the performance of the ELISA and FC methods and to describe the relative flexibility of the ELISA-based assay. Human blood samples encompassing a wide range of levels of P2Y12 blockade achieved in vitro by preincubation with P2Y12 antagonists or in vivo from patients treated with clopidogrel were included, reflecting the wide spread of values reported in clinical studies. The correlation between the PRI measured by ELISA and FC was highly significant (r=0.95, p<0.001), (n=80). After the initial activation, samples were stable for at least four weeks when frozen (–20°C) prior to analysis by ELISA. Frozen samples from patients treated with clopidogrel appeared stable for up to nine weeks. Based on these results, the ELISA-based assay appears to provide a reliable and more flexible alternative to the FC method to determine P2Y12 receptor blockade and may enable more extensive utilisation of the VASP assay in clinical studies.
flow cytometry, clopidogrel, ELISA, VASP, prasugrel
Joseph A. Jakubowski1, Christopher D. Payne2, Ying G. Li1, Nagy A. Farid1, John T. Brandt1, David S. Small1, Daniel E. Salazar3, Kenneth J. Winters1
Thromb Haemost 2008 99 1: 215-222
J. Abtan (1), J. Silvain (1), M. Kerneis (1), S. A. O’Connor (1), O. Barthélémy (1), J.-B. Vignalou (1), F. Beygui (1), D. Brugier (1), J.-P. Collet (1), G. Montalescot (1)
Thromb Haemost 2013 110 5: 1055-1064
Thromb Haemost 2008 99 3: 466-472
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...